Immune support
178 supplements analyzed and ranked by clinical evidence.
Supplement Evidence
Probiotics: fewer infections
Immune calming + barrier
Gut barrier - intestinal permeability
Immune defense - infections -20%
Immune↑ Tregs
Inflammation↓ IL-6
infection↓ 44%
Immune markers +13%
+T cells 12%
Immune boost, fewer infections
Immune suppression, fewer flares
Immune support: -85% infection
Immune support: -13% sores
Inflammation↓, EPA↑
Complications↓, infections↓
Bifido+SCFA, ↓inflammation
Fewer infections, better immunity
Higher immunity +30-90%
More reactogenicity
Boosted immune cells
Reduced inflammation/oxidation
Inflammation↓ IL-6/TNF
Infections↓, vaccine↑
Immune support:+54% seroconversion
Immune support:fewer infections
Lower inflammation, more n‑3
Immune function shifts
Allergy/immune tolerance
+46.6% GSH
Lower IL-6; anti-inflammatory
+70% C, better immunity
Immune markers + infections
T-cell support + less infection
Inflammation down, immunity up
Immune recovery +26.7%
Infections down 26%
T-cell markers up
Milk antibodies, cytokines
Immune transfer, ±10%
Mucosal IgA, +79%
Immune cells↑, infections↓
CRP↓, arginine↑
HIV/CD4: +2.24 risk
Less malaria/anemia: −69%
Immune cells/cytokines: faster clearance
Butyrate↑ immune markers
LPS/inflammation↓ butyrate↑
Lower LTB4/LTE4
AA→EPA/DHA shift
Immune support +14%
GSH↑, immune function
Oxidative/inflammation↓, infections↓
Inflammation↓ immune support
Treg/antioxidant↑ immune support
Immune cells +151
Infections −30%
Immune support, fewer infections
Immune support, faster recovery
GSH↑, immune survival
Inflammation↓, outcomes↑
Anti-inflammatory, gut SCFA
Vaccine antibodies, +10–80%
Immune boost: IgA, T-cells
+35% NK/Phagocytosis
Inflammation down, immunity up
Sepsis/NEC ↓ 46%
Sore throat/cold ↓ 68%
Fewer infections, shorter illness
Lower inflammation, better immunity
↓炎症/免疫 markers
↓airway/respiratory immune reactivity
Inflammation↓, immunity↑
Mortality↓, immunity↑
T-cell boost
WBC increase
Cytokine balance
Inflammation/oxidative stress ↓
Antiviral/immune response ↑
Infection outcomes ↓
Antibody/T cell boost
Rhinitis/asthma relief
Immune recovery + complications
Infections ↓, HLA-DR/TNF-α ↑
Respiratory/infection ↓
Inflammation/immune ↑
ALT/AST, immune↑
Infections, immune defense↓
T-cells, response↑
Immune markers −65%
Inflammation/cytokines reduced
Lower copper, weaker immunity
Fewer infections, better wounds
↑Immune markers with copper
Immune/infection ↓, +5‑fold folate
Inflammation ↓, homocysteine −22%
Neutropenia ↓, WBC +
NK/T cells +43%
Respiratory infections -45%
Basophils -65%
Nasal symptoms -p
Inflammation markers -p
Immune activation +
Inflammation -59% IL-1β
Catheter infections 0 cases
WBC/CRP improvement
Gut barrier/endotoxin ↓
Inflammation markers ↓
Antiviral immunity +20–70%
Warriors, less infections
Gut barrier, microbiota
Inflammation/antiviral boost
Immune cells/antibodies
Lower inflammation
Boosts immune regulation
Leukocyte/antibody boosts
−55% anti‑TPO
−34pp mucositis
Immune markers + B12
Inflammation ↓, antibodies ↑
Immune boost, infections ↓
Cytokines/ALT, +23% remission
Immune cells + pathogens
Cold infections ↓41-58%
NK/cytokines ↑
Infections/colds ↓
Allergy symptom relief
CD4/viral load support
Inflammation down, IL-10 up
Myoglobin down, immune balance
Immune markers +
Gum inflammation ↓
Infection/inflammation ↓
Inflammation down
Endotoxin/immune markers down
Blood pressure down
Skin improvement, ~50%
T-cell shift, no morphology
DLQI -5.9, PASI75 37.5%
Inflammation down, IL-1β/IL-6
CRP/ESR down, TNF-α
Allergy symptoms/IgE
Crohn’s inflammation/remission
Inflammation/oxidative stress ↓
Mucosal/immune protection ↑
Oxidative stress -65%
Inflammation/infection ↓
Inflammation ↓; IL-4/IL-6
Immune balance ↑; IFN-γ
Fewer infections, +antibodies
Immune activation, +IgA/IgG
Omega‑3↑; inflammation↓
Liver markers stable
Inflammation↓, IFN-γ
Oxidative stress↓, 8-isoprostane
Immune cells↑, IL-10
Fewer infections, shorter duration
Lower inflammation, better immunity
NK activity ↑
Inflammation ↓
Inflammation genes ↓
Glucose/IL-6 ↓
Immune activation+antibodies
Inflammation down
T-cell suppression
Reduced inflammation
Immune marker gains
Immune shifts, modestly ↑
MBL/activity changes, risk
Proline/arginine ↑; immunity +
Antibodies ↑; inflammation ↓
Immune markers +10%
Immune suppression -5
Ornithine ↑; lymphocytes ↑
Infections ↓; stay ↓
Immune markers ↑
Antibody boost +8.08
Cold/tonsillitis fewer cases
↓ Salmonella 2–4 log
↑ immune organs/lymphocytes
Immune cells up
Viral reactivation down
CD4+ 60%→37.5%
Anti-inflammatory, antioxidant support
+oocyte outcomes
Cytokines/oxidative stress -
Innate immunity ↑ (NK +34%)
Post-transplant infections ↓ (−10.8%)
UTI defense −51%
Immune cell boost
Lower sting reactions -8%
Higher tolerance markers
Immune recovery
-50% ARDS
Inflammation↓, immunity↑
Flu protection↑ 73%
Immune markers +
Inflammation down, immunity up
Immune markers +
Inflammation −
Amino acids + serine
Immune markers +29%
Immune cells + response
+41% tumor response
Antibody/platelet support
Faster URI recovery
Immune markers ↑
UV immune protection
↓ IL-8, ↑NAD+
T-cell shifts
Fatigue relief
Lower inflammation; -60%
Boosted antiviral response; +38%
↓Inflammation markers
↑Immune cells
Anti-inflammatory genes
−IL-1/TNF-α
Immune/allergy relief
Allergy relief, IgE ↓100
Inflammation control, CRP/ESR ↓
Lymphocytes, +8.9 kg
NK/IL-6, +34.1%
Warts, +11.9 pp
Immune markers −27.9%
Symptoms, inflammation ↓
Inflammation ↓; O2sat +4.8
Immune/eradication ↑; +9.0
Throat/nasal relief +53%
Overall symptoms improved 2.1x
Earache/runny nose reduced
Immune illness↓
Infections↓ 29-38%
Fewer infections, shorter illness
Better autonomic, viral markers
Inflammation, CRP −59%
UTI risk −55%
Antibody boost +8.08
Cold incidence -
Tetanus IgG +
Cough ↓, recovery faster
NK, IgG/IgA/IgM ↑
Immune recovery +28%
Inflammation/allergy −1.7d
Lower inflammation
Better immune markers
↓ T-cell activation
↑ IgA/IgM; ↓ cytokines
Omega-3↑, immune cells↑
Disease activity↓, +3.6% Omega-3
Inflammation -IL-6, TNF-α
Antibacterial support -streptococci
Immune signaling + cells
NLR -reduced
Immune markers down
IL-8 −52.6%
Cytokines down
HPV clearance +14.4%
Inflammation/SpO2 +4.6%
Cu/Se raise immunity
Hepcidin +1.5x, DMT1↓
JAK/STAT ↓; autophagy ↓
Viral clearance ↑; CD4 recovery ↑
Symptoms ↓
IL-6 -55.5%
Lower inflammation
better cytokine balance
Immune markers ↓, +50% TGF-β1
MDRO/AMR burden ↓, A. muciniphila
Symptoms improved, no safety issues
Inflammation ↓; IL-6/8/TNF-α
Immune illness ↓; 28%
Leukopenia response +85%
Rescue use -3.09
↓ inflammation, ↑ microbes
↓ plaque/bleeding, pathogens
Immune markers improved
EDSS better, PUFAs
TNF-α/MDA ↓
Cytokines shifted
RBC preserved
QoL, ABU +26%
Hospital stay −0.95d
Immune modulation: IFN-γ
Inflammation relief: −3.29 SCCAI
DNA damage -40%
T-cells/carotenoids +30%
↓oral pathogens, acid
↓IL-17A (~4.4x)
Inflammation/oxidative stress ↓
IL-6, IFN-γ ↓
No lipid/glucose change
Immune marker up
Respiratory events -29.6%
Immune signalling −43%
Allergic activation −65%
Reduced airway inflammation
Better asthma control
Symptoms -57%
IgE/IgG4 shift
IL-1ra/5/7 ↑
IgE & symptoms ↓
H. pylori, inflammation
NK granzyme B +
HPV clearance 88%
T-cell shifts
Milk +3.3 kg/day
Immune markers ↑
Antibody/PBMC/IFN-γ ↑
Mortality/rehospitalization ↓13.3%
Shorter stay +86%
NK + IFN-γ boost
hsCRP −8.4%
Sore throat relief, 81.6% responders
Earlier antipyretic stop, faster recovery
CD4 +84 cells/µL
No VL or weight change
COVID-19 risk -55%
Mild side effects
TgAb down -46.2
More side effects +37%
NK activity +12%
IFN-γ +1.7 pg/mL
↓ inflammatory markers
↓ TG/VLDL
Anti-inflammatory oxylipins +
Lower IL-6/IL-8
Skin lesions improved
S. aureus inhibited
Endotoxin/MMP-9/IL-18 ↓
Response rate +21.6%
Clearance +21–40%
T/NK + cytokines
Clearance +20%
Cytokines, T-cells up
Function +0.105; activity
Physician/RAQoL/SF-12 improved
Immune vigor, CD4+ T cells
Total/naïve T cells increased
Oral hygiene +0.7
Periodontal scores -1.0
Anti-inflammatory −21% CRP
Oxidative defense +Nrf2
Giardia cleared 100%
Symptoms improved
Relapse/lesion reduction
EDSS/MSFC improved
SNOT-22 -11.6 points
Endoscopic improvement
Vitamin A, antibodies +68%
+128% response, 0% weak
↑beta-cell, ↓IFN-γ
↓insulin dose, ↑IL-4
IL‑1β ↓; symptom relief
No eradication effect
Urticaria - lower UAS7
Quality/sleep better
Acute phase −2 days
Recovery QoL, mental
CRP down; CD4 up
IL-1α/β up
WBC/neutrophils drop less
-13.4% vs -31.5%
T cells unchanged
HDL up, CRP -15%
Triglycerides -15%, Lp-PLA2 -20%
Inflammation -30–66%
Blood pressure/LDL -8%
SIgA +41%/+37%
NK/Th1 cytokines increased
UroA/butyrate↑ CRP↓
Naive CD8↑ metabolism shift
Immune cells shifted +
Bile acids increased
Inflammation -59%
DNA protection ~90%
UTI recurrence -70%
Urgency/incontinence improved
↓IL-6/hs-CRP; ↑TAC
Immune support improved
Mo/Cd damage
Cu boosts antibodies
Mixed immune markers
Non-monotonic dose response
Anti-inflammatory IL-10 +2.2
Glucose control -5.8
Mood maintained; inflammation ↓
BDNF ↓ dose-dependent
Lower inflammation markers
Fibrinogen down
↓TNF-α, neopterin
↑IFNγ/IL-4
T-cells +0.24
Bifidobacterium +29%
Immune age -2y